More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.07B
EPS
-0.45
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
1.693262
Previous close
$15.34
Today's open
$15.27
Day's range
$14.60 - $16.31
52 week range
$10.98 - $28
show more
CEO
Tom Frohlich
Employees
55
Headquarters
Waltham, MA
Exchange
NASDAQ Capital Market
Shares outstanding
69189448
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Jade Biosciences, Inc. (JBIO) Presents at UBS Global Biopharma Conference 2026 Transcript
Jade Biosciences, Inc. ( JBIO ) UBS Global Biopharma Conference 2026 November 16, 2026 7:00 AM EST Company Participants Tom Frohlich - President, CEO & Director Andrew King - President of Research & Development Conference Call Participants Michael Yee - UBS Investment Bank, Research Division Presentation Michael Yee UBS Investment Bank, Research Division All right. I get to say good afternoon.
Seeking Alpha • Nov 16, 2026

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 JADE101 Phase 2 clinical trial in IgA nephropathy (JUNIPER) ongoing; interim data expected in the second quarter of 2027 JADE201 Phase 1 clinical trial in rheumatoid arthritis ongoing; interim data expected in 2027 JADE301 Phase 1 clinical trial in dermatomyositis expected to initiate in the fourth quarter of 2026, with interim data expected in the second half of 2027 Cash, cash equivalents, and investments of $476 million as of September 30, 2026 expected to provide runway into the fourth quarter of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the third quarter ending September 30, 2026, and provided a corporate update. “The third quarter marked another period of meaningful progress for Jade as we advanced each of our development programs toward important clinical milestones,” said Tom Frohlich, Chief Executive Officer of Jade.
GlobeNewsWire • Nov 13, 2026

Jade Biosciences to Participate in Upcoming Conferences
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Fireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ETLocation: Boston, MA Stifel Healthcare Conference Fireside Chat: Wednesday, November 11, 2026 at 10:00 a.m.
GlobeNewsWire • Nov 3, 2026

Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
EVERGREEN Phase 3 Trial-in-Progress poster presents planned study design of JADE101 in IgA nephropathy; initiation now expected in the fourth quarter of 2026 JUNIPER Phase 2 Trial-in-Progress poster highlights ongoing study of JADE101 in IgA nephropathy; interim data now expected in the second quarter of 2027 SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that three posters related to JADE101, a novel, ultra-high affinity and half-life extended investigational anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody in development for the treatment of immunoglobulin A nephropathy (IgAN), will be presented at the American Society of Nephrology (ASN) Kidney Week 2026, being held in Denver, Colorado from October 21-25, 2026. The presentations highlight both the scientific foundation and continued clinical advancement of the JADE101 program in IgAN, including the planned acceleration of the EVERGREEN Phase 3 clinical trial, with initiation now expected in the fourth quarter of 2026.
GlobeNewsWire • Oct 21, 2026

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
Seeking Alpha • Sep 30, 2026

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing JADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cells Following subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscle JADE301 was well tolerated in non-human primates at all evaluated subcutaneous doses Phase 1 healthy volunteer trial expected to begin in the fourth quarter of 2026; interim data anticipated in the second half of 2027 Company to host conference call and webcast today at 8:30 a.m. ET SAN FRANCISCO and VANCOUVER, British Columbia, Sept.
GlobeNewsWire • Sep 30, 2026

Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha • Sep 9, 2026

Jade Biosciences: Duration Is The Real Product
Jade Biosciences (JBIO) targets IgAN with JADE101, aiming for quarterly dosing that could significantly improve patient adherence versus competitors' more frequent regimens. Phase 1 data show JADE101 achieves ~70% IgA reduction with a favorable safety profile; Phase 2 JUNIPER trial interim data expected in 2027 will be pivotal. JBIO's pipeline includes JADE201 (anti-BAFF-R antibody) and JADE301 (IFN-beta inhibitor), both engineered for extended-interval dosing to differentiate in validated autoimmune markets.
Seeking Alpha • Aug 19, 2026

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Announced positive interim Phase 1 results for JADE101 demonstrating potential for every 12-week subcutaneous dosing and best-in-class clinical activity in IgA nephropathy Phase 2 JADE101 clinical trial in IgA nephropathy underway; interim data expected in 2027 Phase 3 JADE101 registrational trial in IgA nephropathy expected to begin in the first half of 2027 Began dosing participants with rheumatoid arthritis in Phase 1 trial of JADE201; interim data expected in 2027 JADE301, a potentially best-in-class, half-life–extended anti-IFN-β for dermatomyositis, now expected to initiate a Phase 1 healthy volunteer trial in the fourth quarter of 2026, with interim data anticipated in second half of 2027 Cash, cash equivalents, and investments of $461 million as of June 30, 2026 expected to provide runway into the fourth quarter of 2028 SAN FRANCISCO and VANCOUVER, British Columbia, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the second quarter ending June 30, 2026, and provided a corporate update. “This was an important period for Jade as we reported positive interim Phase 1 data for JADE101 that exceeded our expectations across biomarker activity and durability, with a favorable safety profile, strengthening our conviction to rapidly advance the compound to deliver a potentially best-in-class profile in IgA nephropathy,” said Tom Frohlich, Chief Executive Officer of Jade Biosciences.
GlobeNewsWire • Aug 10, 2026

Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
SAN FRANCISCO and VANCOUVER, British Columbia, June 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026.
GlobeNewsWire • Jun 26, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Jade Biosciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.